Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.19.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash $ 279,772 $ 11,342
Accounts receivable, net 8,000 29,950
Prepaid expenses 31,458 13,210
Total current assets 319,230 54,502
Property and equipment, net 44,369 19,012
Other assets:    
Patents 15,200
Intellectual property, net 236,000 251,963
Deposits, long term 13,422 13,422
Total other assets 264,622 265,385
Total assets 628,221 338,899
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $32,318 and $62,241, respectively 1,554,652 1,199,536
Deferred revenue, short term 209,474 237,347
Settlement payable 15,000
Convertible notes payable, short term, net of debt discount 3,503,769
Notes payable, short term portion, net of debt discounts of $127,419 672,581
Notes payable, related party 186,590 186,590
Total current liabilities 6,127,066 1,638,473
Long term debt:    
Deferred revenue, long term 207,523 401,346
Convertible notes payable, long term, net of debt discount 2,016,041
Warrant liability 175,975
Total long term debt 207,523 2,593,362
Total liabilities 6,334,589 4,231,835
Commitments and contingencies (Note 17)
Deficit:    
Preferred stock value 16,000 16,000
Common stock, $0.001 par value; 525,000,000 shares authorized, 244,086,285 and 181,804,501 shares issued and outstanding as of December 31, 2017 and 2016, respectively 2,597 2,441
Common stock subscribed 100,000 100,000
Additional paid in capital 49,418,356 44,823,541
Accumulated deficit (55,176,450) (48,840,534)
Total stockholders’ deficit attributable to BioCorRx, Inc. (5,633,881) (3,892,936)
Non-controlling interest (72,487)
Total deficit (5,706,368) (3,892,936)
Total liabilities and deficit 628,221 338,899
Series B Preferred Stock [Member]    
Deficit:    
Preferred stock value $ 5,616 $ 5,616